key: cord-0918299-1jdaiwp4
authors: Kobylecki, Christopher; Jones, Theodora; Lim, Cheng Khuang; Miller, Carol; Thomson, Alexander M
title: Phenomenology and outcomes of in‐patients with Parkinson's disease during COVID‐19 pandemic
date: 2020-06-24
journal: Mov Disord
DOI: 10.1002/mds.28205
sha: 60d1e38f2f77669ba28af88061f10c05d63ea90c
doc_id: 918299
cord_uid: 1jdaiwp4

nan

Compared to a three-year period of control data, we show a higher-than-expected rate of deaths in hospitalised patients with iPD during the pandemic period. As well as apparent high mortality in those positive for COVID-19, indirect effects on mortality in other patients are likely. Delay in seeking medical attention in a pandemic situation is likely to result in more advanced presentations of other conditions. Lack of service capacity to appropriately escalate other non-COVID-19 related acute illness and decompensation in parkinsonism leading to greater vulnerability are further potential indirect mechanisms. Across the reported time period, there was no other significant difference in our hospital services which may have influenced the outcomes seen. There was no bias for seasonal variation in mortality compared to the control group.

This observational study adds to the growing epidemiological data on survival and mortality in COVID-19 illness. Emerging data suggest a high mortality in patients with advanced iPD and COVID-19, 4 as well as worsening of motor and non-motor function. 3 Mortality in moderately affected community-dwelling iPD patients may differ. 5 These results highlight the vulnerability of patients with PD in hospitals and in the community. This work allows us to start to risk stratify this group, and will inform advice on steps to reduce transmission and infection, as well as wider public health approaches. Accepted Article

Origin and evolution of the 2019 novel coronavirus

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Effects of COVID-19 on Parkinson's disease clinical features: a community-based case-control study

Outcome of Parkinson's Disease Patients Affected by COVID-19

COVID-19 in Parkinson's Disease Patients Living in

Kobylecki: research project: conception; statistical analysis: design, execution; manuscript: writing of first draft; review and critique.Jones: research project: conception, execution; manuscript: review and critique.Lim: research project: conception, execution; manuscript: review and critique.Miller: research project: conception, execution; manuscript: review and critique.Thomson: research project: conception, execution; manuscript: writing of first draft, review and critique.

Kobylecki: has received grants from Parkinson's UK and the Michael J Fox Foundation; speaker fees from Britannia and Bial Pharma; support to attend international meetings from Abbvie; advisory boards from Abbvie.Jones: no financial disclosures.Lim: no financial disclosures.Miller: no financial disclosures.

This article is protected by copyright. All rights reserved.Thomson: no financial disclosures.